Clinical Efficacy of ALL-2005 and ALL-2009 Regimen and Factors Influencing Prognosis of Newly Diagnosed ALL Patients Aged between 10-18 Years Old

• Published in: Zhongguo shi yan xue ye xue za zhi Vol. 28; no. 6; p. 1904
• Main Authors: Li, Xiang, Si, Shao-Yong, Cai, Jing-Jing, Qu, Wen-Jing
• Format: Journal Article
• Language: Chinese
• Published: China 01.12.2020
• Subjects: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Disease-Free Survival; Humans; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Prognosis; Retrospective Studies; Treatment Outcome
• ISSN: 1009-2137
• DOI: 10.19746/j.cnki.issn.1009-2137.2020.06.019

To investigate the clinical efficacy of ALL-2005 and ALL-2009 regimen and factors influencing prognosis of newly diagnosed ALL patients aged between 10-18 years old to provide some reference for clinical diagnosis and treatment. The clinical data including baseline clinical characteristics, induction chemotherapy effect, long-term clinical efficacy, recurrence rate and mortality of induction therapy of 119 newly diagnosed ALL patients aged between 10-18 years old from January 2008 to December 2015 were analyzed retrospectively, and the influencing factors of clinical prognosis were evaluated by univariate and multivariate analysis. The complete remission rate at the 5th week after induction therapy was not significantly different between ALL-2005 and ALL-2009 regimen groups (P＞0.05). The cumulative event-free survival rate and overall survival rate of 119 cases after 5-year follow-up were (63.41±3.65)% and (68.95±4.01)% respectively, and after 7-year follow-up were (61.86±3.72)% and (67.22±3.59)% respectively